BRPI0916235A8 - Composto, composição farmacêutica, e, uso do composto ou da composição - Google Patents

Composto, composição farmacêutica, e, uso do composto ou da composição

Info

Publication number
BRPI0916235A8
BRPI0916235A8 BRPI0916235A BRPI0916235A BRPI0916235A8 BR PI0916235 A8 BRPI0916235 A8 BR PI0916235A8 BR PI0916235 A BRPI0916235 A BR PI0916235A BR PI0916235 A BRPI0916235 A BR PI0916235A BR PI0916235 A8 BRPI0916235 A8 BR PI0916235A8
Authority
BR
Brazil
Prior art keywords
compound
composition
compounds
pharmaceutical composition
diseases
Prior art date
Application number
BRPI0916235A
Other languages
English (en)
Inventor
Harper Steven
Summa Vincenzo
J Liverton Nigel
A Mccauley John
Original Assignee
Merck Sharp & Dohme
Msd Italia Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41130248&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0916235(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme, Msd Italia Srl filed Critical Merck Sharp & Dohme
Publication of BRPI0916235A2 publication Critical patent/BRPI0916235A2/pt
Publication of BRPI0916235A8 publication Critical patent/BRPI0916235A8/pt
Publication of BRPI0916235B1 publication Critical patent/BRPI0916235B1/pt
Publication of BRPI0916235B8 publication Critical patent/BRPI0916235B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

COMPOSTO, COMPOSIÇÃO FARMACÊUTICA, E, USO DE UM COMPOSTO A presente invenção diz respeito a compostos de tripiridil carboxamida que são antagonistas de receptores de orexina, e que são usados no tratamento ou prevenção de desordens e doenças neurológicas e psiquiátricas em que receptores de orexina estão envolvidos. A invenção também diz respeito a composições farmacêuticas compreendendo estes compostos e ao uso destes compostos e composições na prevenção ou tratamento de tais doenças em que receptores de orexina estão envolvidos (Formula).
BRPI0916235A 2008-07-22 2009-07-17 composto, composição farmacêutica, e, uso do composto ou da composição BRPI0916235B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13555908P 2008-07-22 2008-07-22
US61/135559 2008-07-22
PCT/US2009/050915 WO2010011566A1 (en) 2008-07-22 2009-07-17 Macrocyclic quinoxaline compounds as hcv ns3 protease inhibitors

Publications (4)

Publication Number Publication Date
BRPI0916235A2 BRPI0916235A2 (pt) 2018-03-13
BRPI0916235A8 true BRPI0916235A8 (pt) 2018-06-12
BRPI0916235B1 BRPI0916235B1 (pt) 2020-09-29
BRPI0916235B8 BRPI0916235B8 (pt) 2021-05-25

Family

ID=41130248

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0916235A BRPI0916235B8 (pt) 2008-07-22 2009-07-17 composto, composição farmacêutica, e, uso do composto ou da composição

Country Status (44)

Country Link
US (2) US7973040B2 (pt)
EP (3) EP2540350B1 (pt)
JP (1) JP4920797B2 (pt)
KR (1) KR101313675B1 (pt)
CN (1) CN102159285B (pt)
AR (1) AR072588A1 (pt)
AU (1) AU2009274190B2 (pt)
BR (1) BRPI0916235B8 (pt)
CA (1) CA2731177C (pt)
CL (1) CL2011000145A1 (pt)
CO (1) CO6351757A2 (pt)
CR (1) CR20110089A (pt)
CY (3) CY1113752T1 (pt)
DK (2) DK2540350T3 (pt)
DO (1) DOP2011000023A (pt)
EA (1) EA019327B1 (pt)
EC (1) ECSP11010777A (pt)
ES (2) ES2491090T3 (pt)
FR (1) FR16C1027I2 (pt)
HK (2) HK1173403A1 (pt)
HN (1) HN2011000209A (pt)
HR (2) HRP20120866T1 (pt)
HU (1) HUS1700001I1 (pt)
IL (1) IL210580A (pt)
LT (1) LTC2310095I2 (pt)
LU (1) LUC00002I2 (pt)
MA (1) MA32502B1 (pt)
ME (2) ME02024B (pt)
MX (1) MX2011000826A (pt)
MY (1) MY152070A (pt)
NI (1) NI201100023A (pt)
NL (1) NL300857I2 (pt)
NO (1) NO2017004I1 (pt)
NZ (1) NZ590638A (pt)
PE (1) PE20110212A1 (pt)
PL (2) PL2540350T3 (pt)
PT (2) PT2310095E (pt)
RS (2) RS53420B (pt)
SI (2) SI2540350T1 (pt)
SV (1) SV2011003813A (pt)
TN (1) TN2011000014A1 (pt)
TW (1) TWI441638B (pt)
UA (1) UA100436C2 (pt)
WO (1) WO2010011566A1 (pt)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
JP5268927B2 (ja) * 2006-10-27 2013-08-21 メルク・シャープ・アンド・ドーム・コーポレーション Ｈｃｖｎｓ３プロテアーゼ阻害剤
EP2271345B1 (en) * 2008-04-28 2015-05-20 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
ES2491090T3 (es) 2008-07-22 2014-09-05 Merck Sharp & Dohme Corp. Combinaciones de un compuesto de quinoxalina macrocíclica que es un inhibidor de la proteasa NS3 del VHC con otros agentes del VHC
US20190127365A1 (en) 2017-11-01 2019-05-02 Merck Sharp & Dohme Corp. Inhibitors of hepatitis c virus replication
JP5913091B2 (ja) 2009-03-27 2016-04-27 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｃ型肝炎ウイルス複製の阻害剤
US8936781B2 (en) * 2009-05-13 2015-01-20 Enanta Pharmaceuticals, Inc. Macrocyclic compounds as hepatitis C virus inhibitors
DK2455376T3 (en) * 2009-06-11 2015-03-02 Abbvie Bahamas Ltd Heterocyclic compounds as inhibitors of hepatitis C virus (HCV)
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
US8828930B2 (en) 2009-07-30 2014-09-09 Merck Sharp & Dohme Corp. Hepatitis C virus NS3 protease inhibitors
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
NZ608720A (en) * 2010-09-21 2015-03-27 Enanta Pharm Inc Macrocyclic proline derived hcv serine protease inhibitors
WO2012050850A1 (en) * 2010-09-29 2012-04-19 Merck Sharp & Dohme Corp. Polycyclic heterocycle derivatives and methods of use thereof for the treatment of viral diseases
JP2013540122A (ja) 2010-09-29 2013-10-31 メルク・シャープ・エンド・ドーム・コーポレイション 縮合四環式化合物誘導体およびウィルス疾患治療のためのそれの使用方法
CA2817365A1 (en) 2010-12-14 2012-06-21 Merck Sharp & Dohme Corp. Process and intermediates for preparing macrolactams
WO2012122716A1 (en) 2011-03-17 2012-09-20 Merck Sharp & Dohme Corp. Tetracyclic xanthene derivatives and methods of use thereof for treatment of viral diseases
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US9249204B2 (en) * 2011-06-01 2016-02-02 Jyant Technologies, Inc. Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof
US9242917B2 (en) 2011-08-19 2016-01-26 Merck Sharp & Dohme Limited Crystal forms of a HCV protease inhibitor
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
UY34401A (es) 2011-10-21 2013-05-31 Abbvie Inc Métodos para el tratamiento de hcv
DE202012012956U1 (de) 2011-10-21 2014-10-16 Abbvie Inc. Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen für die Verwendung zur Behandlung von HCV, umfassend Ribavirin aber nicht Interferon
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
EP2773342A4 (en) * 2011-10-31 2015-08-26 Merck Sharp & Dohme COMPOSITIONS USEFUL FOR THE TREATMENT OF VIRAL DISEASES
WO2013074386A2 (en) 2011-11-15 2013-05-23 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
ES2613766T3 (es) 2012-10-19 2017-05-25 Bristol-Myers Squibb Company Derivados de carbamato de hexadecahidrociclopropa(e)pirrolo(1,2-a)(1,4)diazaciclopentadecinilo sustituidos con 9-metilo como inhibidores de la proteasa no estructural 3 (NS3) para el tratamiento de infecciones del virus de la hepatitis C
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9598433B2 (en) 2012-11-02 2017-03-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914598B1 (en) 2012-11-02 2017-10-18 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9409943B2 (en) 2012-11-05 2016-08-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014110687A1 (en) 2013-01-16 2014-07-24 Merck Sharp & Dohme Corp. Thiazolyl-substitued tetracyclic compounds and methods of use thereof for treatment of viral diseases
JP6342922B2 (ja) 2013-03-07 2018-06-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ型肝炎ウイルス阻害剤
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
US9617310B2 (en) * 2013-03-15 2017-04-11 Gilead Sciences, Inc. Inhibitors of hepatitis C virus
CN105636923A (zh) * 2013-10-18 2016-06-01 默沙东公司 用于制备大环内酯酰胺的方法和中间体
WO2015095430A1 (en) * 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Methods and intermediates for the preparation of macrolactams
CN116813596A (zh) 2013-12-23 2023-09-29 吉利德科学公司 大环hcv ns3抑制三肽的合成
EP3087086B1 (en) * 2013-12-23 2018-11-07 Gilead Sciences, Inc. Crystalline forms of a macrocyclic hcv ns3 inhibiting tripeptide
EP3089757A1 (en) 2014-01-03 2016-11-09 AbbVie Inc. Solid antiviral dosage forms
CA2937942A1 (en) * 2014-02-05 2015-08-13 Merck Sharp & Dohme Corp. Fixed-dose combinations of antiviral compounds
WO2015119919A1 (en) * 2014-02-05 2015-08-13 Merck Sharp & Dohme Corp. Pharmaceutical composition of selective hcv ns3/4a inhibitors
MX2016016127A (es) 2014-06-06 2017-02-23 Abbvie Inc Formas cristalinas.
WO2017023714A1 (en) * 2015-08-04 2017-02-09 Merck Sharp & Dohme Corp. Fixed-dose combinations of antiviral compounds
WO2017023716A1 (en) * 2015-08-04 2017-02-09 Merck Sharp & Dohme Corp. Fixed-dose combinations of antiviral compounds
CN105753806B (zh) * 2016-02-02 2018-06-05 厦门市蔚嘉化学科技有限公司 一种利托那韦中间体的非均相合成方法及其应用
WO2017189978A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
CN109562113A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的螺环降解决定子体
EP3454856A4 (en) 2016-05-10 2019-12-25 C4 Therapeutics, Inc. HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN REDUCTION
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
CN112661775A (zh) * 2016-05-16 2021-04-16 深圳市塔吉瑞生物医药有限公司 一种取代的大环喹喔啉化合物及其药物组合物及应用
RU2650610C1 (ru) 2017-02-28 2018-04-16 Васильевич Иващенко Александр Противовирусная композиция и способ ее применения
WO2020247736A1 (en) * 2019-06-07 2020-12-10 University Of Massachusetts Hepatitis c virus ns3/4a protease inhibitors
CN111057045A (zh) * 2019-12-18 2020-04-24 安徽红杉生物医药科技有限公司 Hcv ns3/4a蛋白酶抑制剂中间体及其合成方法、应用
WO2021209563A1 (en) 2020-04-16 2021-10-21 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3480613A (en) 1967-07-03 1969-11-25 Merck & Co Inc 2-c or 3-c-alkylribofuranosyl - 1-substituted compounds and the nucleosides thereof
US6128582A (en) 1996-04-30 2000-10-03 Vertex Pharmaceuticals Incorporated Molecules comprising an IMPDH-like binding pocket and encoded data storage medium capable of graphically displaying them
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
GB9707659D0 (en) 1997-04-16 1997-06-04 Peptide Therapeutics Ltd Hepatitis C NS3 Protease inhibitors
HUP0004853A3 (en) 1997-08-11 2001-12-28 Boehringer Ingelheim Ca Ltd Hepatitis c inhibitor peptides, process for preparation thereof, pharmaceutical compositions comprising thereof, their use and their intermediates
JP4452401B2 (ja) 1997-08-11 2010-04-21 ベーリンガー インゲルハイム （カナダ） リミテッド Ｃ型肝炎ウイルス阻害ペプチドアナログ
IT1299134B1 (it) 1998-02-02 2000-02-29 Angeletti P Ist Richerche Bio Procedimento per la produzione di peptidi con proprieta' inibitrici della proteasi ns3 del virus hcv, peptidi cosi' ottenibili e peptidi
IL138037A0 (en) 1998-02-25 2001-10-31 Univ Emory 2'-fluoronucleosides
GB9806815D0 (en) 1998-03-30 1998-05-27 Hoffmann La Roche Amino acid derivatives
EP1066247B1 (en) 1998-03-31 2006-11-22 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
GB9812523D0 (en) 1998-06-10 1998-08-05 Angeletti P Ist Richerche Bio Peptide inhibitors of hepatitis c virus ns3 protease
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
US6602982B1 (en) 1998-08-10 2003-08-05 Hokkaido Electric Power Company, Incorporated Process for the preparation of regular glycopeptides
CA2348234A1 (en) 1998-10-29 2000-05-11 Chunjian Liu Compounds derived from an amine nucleus that are inhibitors of impdh enzyme
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
UA74546C2 (en) 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
DE60005017T2 (de) 1999-06-25 2004-06-09 Vertex Pharmaceuticals Inc., Cambridge Prodrugs von impdh-inhibierenden carbamaten
CA2363274A1 (en) 1999-12-27 2001-07-05 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs for hepatitis c
US6495677B1 (en) 2000-02-15 2002-12-17 Kanda S. Ramasamy Nucleoside compounds
US6455508B1 (en) 2000-02-15 2002-09-24 Kanda S. Ramasamy Methods for treating diseases with tirazole and pyrrolo-pyrimidine ribofuranosyl nucleosides
PL364995A1 (en) 2000-02-18 2004-12-27 Shire Biochem Inc. Method for the treatment or prevention of flavivirus
EP1268525B1 (en) 2000-04-05 2008-12-31 Schering Corporation Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising n-cyclic p2 moieties
US6727267B2 (en) 2000-04-05 2004-04-27 Tularik Inc. NS5B HVC polymerase inhibitors
US7094770B2 (en) 2000-04-13 2006-08-22 Pharmasset, Ltd. 3′-or 2′-hydroxymethyl substituted nucleoside derivatives for treatment of hepatitis virus infections
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
CN1315862C (zh) 2000-05-26 2007-05-16 艾登尼科斯（开曼）有限公司 处理黄病毒和瘟病毒的方法和组合物
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
GB0017676D0 (en) 2000-07-19 2000-09-06 Angeletti P Ist Richerche Bio Inhibitors of viral polymerase
WO2002014376A2 (en) 2000-08-10 2002-02-21 Trustees Of Boston College Recyclable metathesis catalysts
US6955174B2 (en) 2000-08-18 2005-10-18 Uryovascular Systems, Inc. Cryotherapy method for detecting and treating vulnerable plaque
US20030008841A1 (en) 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
US6809101B2 (en) 2000-09-01 2004-10-26 Shionogi & Co., Ltd. Compounds having anti-hepatitis C virus effect
CN1646141B (zh) 2000-10-18 2014-06-25 吉利德制药有限责任公司 用于治疗病毒感染和异常细胞增殖的修饰核苷类化合物
AU3659102A (en) 2000-12-12 2002-06-24 Schering Corp Diaryl peptides as ns3-serine protease inhibitors of hepatits c virus
AU2002230763A1 (en) 2000-12-13 2008-01-03 Bristol-Myers Squibb Pharma Company Inhibitors of hepatitis c virus ns3 protease
AU2002232660A1 (en) 2000-12-15 2002-06-24 Pharmasset Ltd. Antiviral agents for treatment of flaviviridae infections
WO2002051425A1 (fr) 2000-12-26 2002-07-04 Mitsubishi Pharma Corporation Remedes pour l'hepatite c
EP1707571B1 (en) 2001-01-22 2011-09-28 Merck Sharp & Dohme Corp. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
GB0114286D0 (en) 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
US7544374B2 (en) 2001-08-14 2009-06-09 Tel Aviv University Future Technology Development L.P. Lipidated glycosaminoglycan particles and their use in drug and gene delivery for diagnosis and therapy
WO2003026675A1 (en) 2001-09-28 2003-04-03 Idenix (Cayman) Limited Methods and compositions for treating flaviviruses and pestiviruses using 4'-modified nucleoside
US7138376B2 (en) 2001-09-28 2006-11-21 Idenix Pharmaceuticals, Inc. Methods and compositions for treating hepatitis C virus using 4'-modified nucleosides
US7282512B2 (en) 2002-01-17 2007-10-16 Smithkline Beecham Corporation Cycloalkyl ketoamides derivatives useful as cathepsin K inhibitors
GB0201179D0 (en) 2002-01-18 2002-03-06 Angeletti P Ist Richerche Bio Therapeutic agents
CA2369711A1 (en) 2002-01-30 2003-07-30 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis c virus
US7323453B2 (en) 2002-02-13 2008-01-29 Merck & Co., Inc. Methods of inhibiting orthopoxvirus replication with nucleoside compounds
DE60202603T2 (de) 2002-03-28 2005-12-29 Council Of Scientific And Industrial Research 8-(c-beta-d-glucopyranosyl)-7,3',4'-trihydroxyflavone, verfahren zur isolation aus pterocarpus marsupium und pharmazeutische zusammensetzung zur behandlung von diabetes
AU2003232071A1 (en) 2002-05-06 2003-11-17 Genelabs Technologies, Inc. Nucleoside derivatives for treating hepatitis c virus infection
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
EP1551421A2 (en) 2002-06-21 2005-07-13 Merck & Co. Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
JP2006512288A (ja) 2002-06-27 2006-04-13 メルク　エンド　カムパニー　インコーポレーテッド Ｒｎａ依存性ｒｎａウィルスポリメラーゼ阻害薬としてのヌクレオシド誘導体
AP2005003211A0 (en) 2002-06-28 2005-03-31 Idenix Cayman Ltd 1'-,2'-and 3'-modified nucleoside derivatives for treating flaviviridae infections.
US7456155B2 (en) 2002-06-28 2008-11-25 Idenix Pharmaceuticals, Inc. 2′-C-methyl-3′-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
CN103319554A (zh) 2002-06-28 2013-09-25 埃迪尼克斯医药公司 用于治疗黄病毒感染的修饰的2’和3’-核苷前药
JP2005533108A (ja) 2002-07-16 2005-11-04 メルク　エンド　カムパニー　インコーポレーテッド Ｒｎａ依存性ｒｎａウイルスポリメラーゼの阻害剤としてのヌクレオシド誘導体
EP1527082A2 (en) 2002-07-25 2005-05-04 Micrologix Biotech, Inc. Anti-viral 7-deaza d-nucleosides and uses thereof
US8093380B2 (en) 2002-08-01 2012-01-10 Pharmasset, Inc. Compounds with the bicyclo[4.2.1]nonane system for the treatment of Flaviviridae infections
EP1572097A4 (en) 2002-09-30 2010-02-17 Smithkline Beecham Corp NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF INFECTIONS WITH THE HEPATITIS C-VIRUS
NZ539727A (en) 2002-11-01 2008-01-31 Viropharma Inc Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases
US20040254159A1 (en) 2003-02-27 2004-12-16 Hasvold Lisa A. Heterocyclic kinase inhibitors
JP4550824B2 (ja) 2003-03-05 2010-09-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎抑制化合物
WO2004093915A1 (en) 2003-04-02 2004-11-04 Boehringer Ingelheim International, Gmbh Pharmaceutical compositions for hepatitis c viral protease inhibitors
GB0307891D0 (en) 2003-04-04 2003-05-14 Angeletti P Ist Richerche Bio Chemical compounds,compositions and uses
WO2004094452A2 (en) 2003-04-16 2004-11-04 Bristol-Myers Squibb Company Macrocyclic isoquinoline peptide inhibitors of hepatitis c virus
US7176208B2 (en) 2003-04-18 2007-02-13 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
EA009295B1 (ru) 2003-05-21 2007-12-28 Бёрингер Ингельхайм Интернациональ Гмбх Соединения в качестве ингибиторов вируса гепатита с
ES2726998T3 (es) 2003-05-30 2019-10-11 Gilead Pharmasset Llc Análogos de nucleósidos fluorados modificados
GB0313250D0 (en) 2003-06-09 2003-07-16 Angeletti P Ist Richerche Bio Therapeutic agents
CN1809582A (zh) 2003-06-19 2006-07-26 弗·哈夫曼-拉罗切有限公司 制备4＇－叠氮基核苷衍生物的方法
TW200510425A (en) 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
GB0321003D0 (en) 2003-09-09 2003-10-08 Angeletti P Ist Richerche Bio Compounds, compositions and uses
GB0323845D0 (en) 2003-10-10 2003-11-12 Angeletti P Ist Richerche Bio Chemical compounds,compositions and uses
US7132504B2 (en) 2003-11-12 2006-11-07 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
DE602005025855D1 (de) 2004-01-21 2011-02-24 Boehringer Ingelheim Pharma Makrocyclische peptide mit wirkung gegen das hepatitis-c-virus
PT1719773E (pt) 2004-02-24 2009-06-03 Japan Tobacco Inc Compostos heterotetracíclicos fundidos e a sua utilização como inibidores da polimerase do hcv
GB0413087D0 (en) 2004-06-11 2004-07-14 Angeletti P Ist Richerche Bio Therapeutic compounds
GB0416396D0 (en) 2004-07-22 2004-08-25 Angeletti P Ist Richerche Bio Therapeutic agents
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
CN101044151B (zh) 2004-08-23 2011-01-19 弗·哈夫曼-拉罗切有限公司 抗病毒的4＇-叠氮基-核苷
GB0419850D0 (en) 2004-09-07 2004-10-13 Angeletti P Ist Richerche Bio Therapeutic agents
MX2007004979A (es) 2004-10-26 2007-06-14 Angeletti P Ist Richerche Bio Derivados de indol tetraciclicos como agentes antiviricos.
US7834145B2 (en) 2005-03-22 2010-11-16 Merck Sharp & Dohme Corp. HCV protease substrates
CA2606195C (en) 2005-05-02 2015-03-31 Merck And Co., Inc. Hcv ns3 protease inhibitors
GB0509326D0 (en) 2005-05-09 2005-06-15 Angeletti P Ist Richerche Bio Therapeutic compounds
AR057456A1 (es) 2005-07-20 2007-12-05 Merck & Co Inc Inhibidores de la proteasa ns3 del vhc
US7462035B2 (en) 2005-07-27 2008-12-09 Physical Optics Corporation Electrical connector configured as a fastening element
MX2008001588A (es) 2005-08-01 2008-02-19 Merck & Co Inc Inhibidores de proteasa ns3 del vhc.
WO2007028789A1 (en) 2005-09-07 2007-03-15 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Quinazoline derivatives as antiviral agents
GB0518390D0 (en) 2005-09-09 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
GB0519797D0 (en) 2005-09-29 2005-11-09 Istituto Di Ricerche D Biolog Therapeutic agents
GB0609492D0 (en) 2006-05-15 2006-06-21 Angeletti P Ist Richerche Bio Therapeutic agents
WO2007145894A2 (en) 2006-06-08 2007-12-21 Merck & Co., Inc. A rapid method to determine inhibitor sensitivity of ns3/4a protease sequences
GB0612423D0 (en) 2006-06-23 2006-08-02 Angeletti P Ist Richerche Bio Therapeutic agents
UY30437A1 (es) * 2006-06-26 2008-01-31 Enanta Pharm Inc Quinoxalinil macroceclicos inhibidores de serina proteasa del virus de la hepatitis c
WO2008051475A2 (en) * 2006-10-24 2008-05-02 Merck & Co., Inc. Hcv ns3 protease inhibitors
US8377873B2 (en) 2006-10-24 2013-02-19 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
US8309540B2 (en) 2006-10-24 2012-11-13 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
JP5268927B2 (ja) * 2006-10-27 2013-08-21 メルク・シャープ・アンド・ドーム・コーポレーション Ｈｃｖｎｓ３プロテアーゼ阻害剤
CA2667032A1 (en) * 2006-10-27 2008-05-15 Merck & Co., Inc. Hcv ns3 protease inhibitors
WO2008057028A1 (en) 2006-11-09 2008-05-15 Twinblade Technologies Holding Sweden Ab Hub device
EP2118301A4 (en) 2007-03-09 2011-04-20 Merck Sharp & Dohme IN VIVO RESISTANCE OF HCV TO ANTI-VIRAL INHIBITORS
PT2170888E (pt) 2007-06-29 2015-08-21 Gilead Sciences Inc Purina derivados e sua utilização como moduladores de recetor de tipo toll 7
AU2008277377B2 (en) 2007-07-19 2013-08-01 Msd Italia S.R.L. Macrocyclic compounds as antiviral agents
EP2219454A4 (en) 2007-11-14 2012-05-30 Enanta Pharm Inc HEMMER OF MACROCYCLIC TETRAZOLYL HEPATITIS C SERIN PROTEASE
CL2008003384A1 (es) 2007-11-14 2009-12-11 Enanta Pharm Inc Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c.
EP2271345B1 (en) * 2008-04-28 2015-05-20 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
ES2491090T3 (es) 2008-07-22 2014-09-05 Merck Sharp & Dohme Corp. Combinaciones de un compuesto de quinoxalina macrocíclica que es un inhibidor de la proteasa NS3 del VHC con otros agentes del VHC

Also Published As

Publication number Publication date
BRPI0916235A2 (pt) 2018-03-13
SI2310095T1 (sl) 2013-01-31
FR16C1027I2 (fr) 2017-12-08
HRP20140693T1 (hr) 2014-11-21
AU2009274190B2 (en) 2012-07-05
IL210580A (en) 2014-08-31
NO2017004I2 (no) 2017-01-20
ME02132B (me) 2014-08-22
CY2017005I1 (el) 2017-06-28
US7973040B2 (en) 2011-07-05
CN102159285B (zh) 2014-05-14
FR16C1027I1 (fr) 2017-02-03
CY1115503T1 (el) 2017-01-04
AR072588A1 (es) 2010-09-08
DK2310095T3 (da) 2012-12-10
MX2011000826A (es) 2011-02-23
IL210580A0 (en) 2011-03-31
CN102159285A (zh) 2011-08-17
MA32502B1 (fr) 2011-07-03
MY152070A (en) 2014-08-15
CL2011000145A1 (es) 2011-05-06
HK1173402A1 (en) 2013-05-16
PL2310095T3 (pl) 2013-03-29
TW201023860A (en) 2010-07-01
LTC2310095I2 (lt) 2018-11-12
TWI441638B (zh) 2014-06-21
LUC00002I1 (pt) 2017-01-19
CR20110089A (es) 2011-04-27
PT2540350E (pt) 2014-08-27
SV2011003813A (es) 2011-05-25
LTPA2016049I1 (lt) 2017-01-25
KR20110036627A (ko) 2011-04-07
HRP20120866T1 (hr) 2013-01-31
CA2731177A1 (en) 2010-01-28
LUC00002I2 (pt) 2017-04-04
NI201100023A (es) 2011-09-20
JP4920797B2 (ja) 2012-04-18
PL2540350T3 (pl) 2014-10-31
CY1113752T1 (el) 2016-07-27
HK1173403A1 (en) 2013-05-16
EP2310095A1 (en) 2011-04-20
TN2011000014A1 (en) 2012-09-05
KR101313675B1 (ko) 2013-10-02
EP2310095B1 (en) 2012-08-29
ES2392611T3 (es) 2012-12-12
JP2011528713A (ja) 2011-11-24
US20110224134A1 (en) 2011-09-15
NL300857I2 (pt) 2017-04-25
HN2011000209A (es) 2013-04-22
NZ590638A (en) 2012-06-29
AU2009274190A1 (en) 2010-01-28
WO2010011566A1 (en) 2010-01-28
US8080654B2 (en) 2011-12-20
ME02024B (me) 2015-05-20
DOP2011000023A (es) 2011-03-31
CA2731177C (en) 2013-10-29
BRPI0916235B1 (pt) 2020-09-29
NO2017004I1 (no) 2017-01-20
EP2540350A1 (en) 2013-01-02
HUS1700001I1 (hu) 2017-02-28
EA201170241A1 (ru) 2011-10-31
CY2017005I2 (el) 2017-06-28
ECSP11010777A (es) 2011-02-28
PE20110212A1 (es) 2011-04-10
EP2540349A1 (en) 2013-01-02
EP2540350B1 (en) 2014-05-21
EP2540349B1 (en) 2014-02-12
ES2491090T3 (es) 2014-09-05
RS53420B (en) 2014-12-31
DK2540350T3 (da) 2014-08-04
RS52534B (en) 2013-04-30
CO6351757A2 (es) 2011-12-20
BRPI0916235B8 (pt) 2021-05-25
UA100436C2 (en) 2012-12-25
SI2540350T1 (sl) 2015-01-30
US20100029666A1 (en) 2010-02-04
PT2310095E (pt) 2012-11-16
EA019327B1 (ru) 2014-02-28

Similar Documents

Publication Publication Date Title
BRPI0916235A8 (pt) Composto, composição farmacêutica, e, uso do composto ou da composição
EA201170624A1 (ru) Изоникотинамидные антагонисты рецепторов орексинов
NO20092470L (no) Substituerte diazepanforbindelser som orexinreseptorantagonister
DE602007008434D1 (de) Rezeptoren
MY148544A (en) Pyridyl piperidine orexin receptor antagonists
WO2008008551A3 (en) 2-substituted proline bis-amide orexin receptor antagonists
UA100974C2 (ru) Соединения замещенных диазепанов как антагонисты орексиновых рецепторов
MX2008012400A (es) Azolopirimidinas como inhibidores de actividad de cannabinoide 1.
WO2007126934A3 (en) Amidoethylthioether orexin receptor antagonists
MX2008002805A (es) Derivados de carboxamida como antagonistas del receptor muscarinico.
WO2009120652A3 (en) Monocyclic cgrp receptor antagonists
ATE455111T1 (de) Einen azepin-kern enthaltende antagonisten des histaminrezeptors
DE602007005387D1 (de) Ptors
UA101367C2 (en) Normal;heading 1;heading 2;heading 3;HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS
UA89846C2 (ru) Производные карбоксамида как антагонисты мускариновых рецепторов

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANG

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANG

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25G Requested change of headquarter approved

Owner name: ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANG

B25G Requested change of headquarter approved

Owner name: ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) , MERCK SHARP AND DOHME CORP. (US)

Owner name: ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANG

B25A Requested transfer of rights approved

Owner name: MERCK SHARP AND DOHME CORP. (US) ; MSD ITALIA S.R.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/09/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/07/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25A Requested transfer of rights approved

Owner name: MSD ITALIA S.R.L. (IT) ; MERCK SHARP AND DOHME LLC (US)